Response to: The BRAIN TRIAL: A randomised, placebo controlled trial of a Bradykinin B2 receptor antagonist (Anatibant) in patients with traumatic brain injury

Trials

Volumn 10, Issue , 2009, Pages

  Simmon, Vincent F ^a  

^a Xytis Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANATIBANT; PLACEBO; UNCLASSIFIED DRUG; XY 2405; BRADYKININ B2 RECEPTOR; QUINOLINE DERIVATIVE;

ACCESS TO INFORMATION; CLINICAL TRIAL; DEATH; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG MEGADOSE; DRUG SAFETY; GLASGOW COMA SCALE; HUMAN; LETTER; LOW DRUG DOSE; MORBIDITY; MORTALITY; SYSTEMATIC ERROR; TRAUMATIC BRAIN INJURY; BRAIN INJURY; DRUG ANTAGONISM; NOTE; RANDOMIZED CONTROLLED TRIAL;

BRAIN INJURIES; HUMANS; PLACEBOS; QUINOLINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTOR, BRADYKININ B2;

EID: 73249153460     PISSN: 17456215     EISSN: 17456215     Source Type: Journal    
DOI: 10.1186/1745-6215-10-110     Document Type: Letter

References (1)

1. Shakur H, Andrews P, Asser T, Balica L, Boeriu C, Ciro Quintero JD, Dewan Y, Druwé P, Fletcher O, Frost C, Hartzenberg B, Mejia Mantilla J, Murillo-Cabezas F, Pachl J, Ravi RR, Rätsep I, Sampaio C, Singh M, Svoboda P, Roberts I. The BRAIN TRIAL: a randomised, placebo controlled trial of a Bradykinin B2 receptor antagonist (Anatibant) in patients with traumatic brain injury. Trials 2009, 10:109.